Follow this link: XORTX Announces $2 Million Public Offering
Follow this link: XORTX Announces $2 Million Public Offering
Read the original: GENFIT Announces 2024 Financial Calendar
Link: AB Science receives notice of allowance for European patent covering masitinib until 2036 in the treatment of mastocytosis
Read this article: European Commission approves Roche’s Tecentriq SC, the EU's first PD-(L)1 cancer immunotherapy subcutaneous injection for multiple cancer types
Read more here: PolTREG receives US Patent Office Notice of Allowance for Treg cell therapy to treat Type-1 Diabetes
Original post: Ultimovacs Updates Timeline for Reporting on Randomized UV1 Phase II Trial INITIUM in Malignant Melanoma; Topline Results expected in March 2024
Read the original here: Majority of Individuals with Atopic Dermatitis Improved with Arcutis’ Roflumilast Cream 0.15% According to New Data from Phase 3 Program
View original post here: (Updated) U.S. Legal Cannabis Pioneer Bright Green Corporation Appoints Industry Veteran Groovy Singh as New Chief Executive Officer
Continue reading here: ZORYVE® (Roflumilast) Topical Foam, 0.3% Clears Seborrheic Dermatitis in Individuals Who Previously Reported an Inadequate Response to Topical...
Read more here: Key information relating to the cash dividend to be paid by Vistin Pharma ASA
Recent Comments